Autologous stromal vascular fraction therapy for rheumatoid arthritis: rationale and clinical safety

@inproceedings{Rodriguez2012AutologousSV,
  title={Autologous stromal vascular fraction therapy for rheumatoid arthritis: rationale and clinical safety},
  author={Jorge Paz Rodriguez and Michael P Murphy and Soon Jun Hong and Marialaura Madrigal and Keith L. March and Boris R. Minev and Robert J. Harman and Chien-shing Chen and Ruben Berrocal Timmons and Annette M. Marleau and Neil H. Riordan},
  booktitle={International archives of medicine},
  year={2012}
}
Advancements in rheumatoid arthritis (RA) treatment protocols and introduction of targeted biological therapies have markedly improved patient outcomes, despite this, up to 50% of patients still fail to achieve a significant clinical response. In veterinary medicine, stem cell therapy in the form of autologous stromal vascular fraction (SVF) is an accepted therapeutic modality for degenerative conditions with 80% improvement and no serious treatment associated adverse events reported. Clinical… CONTINUE READING
BETA
Tweets
This paper has been referenced on Twitter 3 times. VIEW TWEETS

Citations

Publications citing this paper.
SHOWING 1-10 OF 11 CITATIONS

References

Publications referenced by this paper.
SHOWING 1-10 OF 152 REFERENCES

Mesenchymal stem cells for treatment of steroidresistant, severe, acute graft-versus-host disease: a phase II study

  • K Le Blanc
  • Lancet ,
  • 2012
2 Excerpts

Similar Papers

Loading similar papers…